Contrast-induced nephropathy (Pharmacology of X-ray contrast agents)

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access


In the last 30 years the use of X-ray contrast media (RCM) has increased significantly during urography, angiography, computed tomography, and operating procedures. Every year the world uses about 60 million doses of PKM, but, despite the use of newer and less nephrotoxic drugs, the risk of contrast-induced nephropathy (CIN) is still significant, especially among patients with prior renal impairment. Contrast induced nephropathy is a major cause of acute renal injury and is a huge problema in clinical practice. So far, con-tradictions remain in the understanding of many aspects of CIN. Contrast-induced nephropathy is acute renal failure (ARF) occurs within 48-72 hours after intravenous administration of contrast sub-stances. Toxicity PKC determined their molecular structure and its ability to dissociate in aqueous solution into ions which consist of salts which dissociate into cations and anions. The contrast-induced nephropathy is manifested in the increase of serum creatinine of 44 mmol/L (0.5 mg / dl) or more and the same rise in serum creatinine of more than 25 % compared to baseline in the absence of other possible causes. ARF is a sudden and sustained reduction in glomerular filtration rate and urine volume, or both together. Thus renal dysfunction existing even more than 1 month can be regarded as acute renal dysfunction. Usually the development of acute renal failure occurs within 1-7 days. The criteria of sustainability is a dysfunction of its registration within 24 hours or more. The aim: to consider different approaches to the pathogenesis, risk factors and achievements in the prevention of contrast-induced nephropathy.

Full Text

Restricted Access

About the authors

Vladislava A Raptanova

First St. Petersburg State Medical University

Doctor-Intern, the Department of Radiology and Radiation Medicine with Division of Rentgenology. State Budget Educational Institution “The First St. Petersburg State Medical University”.

Alexandra A Speranskaya

First St. Petersburg State Medical University

MD, PhD, Dr Med Sci, Professo. Department of Radiology and Radiation Medicine with Division of Rentgenology. State Budget Educational Institution “The First St. Petersburg State Medical University”.

Sergei N Proshin

Saint Petersburg State Pediatric Medical University of Health Ministry of Russia

MD, PhD, Dr Med Sci, Professor, Head of the Department of Pharmacology. St. Petersburg State Pediatric Medical University.


  1. Каюков И. Г. Рентгеноконтрастная нефропатия ГОЭТАР-Медиа. - М., 2009. [Kauykov IG. Radiopaque nephropathy. GOETAR-Mediya. Мoscow; 2009. (In Russ).]
  2. Aspelin P. Nephrotoxic Effects in High-Risk Patients Undergoing Angiography. N Engl J Med. 2003;348(6):491-9.doi: 10.1056/nejmoa021833.
  3. Cigarroa RG, Lange RA, Williams RH. Dosing of contrast material to prevent contrast nephropathy in patients with renal disease. Am J Med. 1989;86(6):649-52. doi: 10.1016/0002-9343(89)90437-3.
  4. Gleeson T. Contrast-Induced Nephropathy. Buluga¬hapi¬tiya. 2004;183(6):1673-89. doi: 10.2214/ajr.183.6.01831673.
  5. Hernandez F. Multivariable prediction of renal insufficiency developing after cardiac surgery. Eur Heart J. 2007;28 (Abstract Supplement):454-463.
  6. Kappel J. Nephrology: 3. Safe drug prescribing for patients with renal insufficiency. 2002;166:473-7.
  7. Morcos SK. Prevention of contrast media nephrotoxicity - the story so far. Clin Radiol. 2004; 59(5):381-9. doi: 10.1016/j.crad.2003.11.005.
  8. Rezkalla SH. Contrast Nephropathy. 2003;1(4):301-4.
  9. Solomon RJ. Cardiac Angiography in renally Impaired Patients (CARE) Study. A Randomized Double-Blind Trial of Contrast-Induced Nephropathy in Patients With Chronic Kidney Disease. Circulation. 2007.
  10. Thomsen HS. Contrast media and the kidney: European Society of Urogenital Radiology (ESUR) Guidelines. British J of Radiol. 2003;76(908):513-8. doi: 10.1259/bjr/26964464.
  11. Thomsen HS, Morcos SK, Erley CM. The ACTIVETrial: comparison of the effects on renal function of iomeprol-400 and iodixanol-320 in patients with chronic kidney disease undergoing abdominal computed tomography. Invest Radiol. 2008;43(3):170-8. doi: 10.1097/rli.0b013e31815f3172.



Abstract - 1079

PDF (Russian) - 929


Article Metrics

Metrics Loading ...



Copyright (c) 2016 Raptanova V.A., Speranskaya A.A., Proshin S.N.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies